MA-ALSYM-ENERGY
Alsym™ Energy, a developer of next-generation rechargeable batteries, today announced that Alsym and Synergy Marine, in collaboration with Nissen Kaiun, Japan, will jointly develop applications specific to the marine shipping industry using Alsym’s high-performance, low-cost technology. Singapore-based Synergy Marine is a leading global ship management services provider, currently managing more than 500 vessels.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220720005100/en/
Greenhouse gases from ships are predicted to make up 17% of total global emissions by 2050 if the industry does not accelerate efforts to electrify. Port operations generate substantial amounts of air pollution—up to half of total emissions in some metro areas—and some ports now require ships to use high efficiency fuels and observe speed limits within 20 miles of shore, while others have banned the use of auxiliary diesel generators while docked.
Alsym will provide Synergy and Nissen Kaiun with 1 gigawatt of batteries per year for three years starting in the company’s first year of high-volume production, conditional on the battery systems meeting key performance levels and regulatory requirements specific to cargo ships and tankers. Alsym’s batteries may be used to propel cargo ships and tankers as they enter and leave port, power berthed ships, and support peak shaving applications at sea. The company plans to start pilot manufacturing its non-flammable batteries for EVs, ships, and stationary storage later this year at its facility in Massachusetts, with high-volume production expected to follow in 2025.
“Zero-emission vessels are the future of maritime shipping, and we’re working with like-minded owners, including Nissen Kaiun, to decarbonize every part of the ecosystem as quickly as possible,” said Captain Rajesh Unni, Founder and CEO of Synergy Marine Group. “By lowering the cost of electrification and minimizing the risk of battery-related fire events, Alsym’s technology is well-placed to be a safer alternative that can help the shipping industry meet its goal of zero net emissions by 2050—especially in light of the European Commission’s recent proposal to classify lithium as toxic.”
By using low-cost, inherently non-flammable raw materials with robust global supply chains, Alsym’s aims to provide batteries at a fraction of the cost of lithium-based technologies, making electrification both safe and economically viable. These batteries can help reduce risks to crew and cargo, as well as lower insurance costs for fleet managers and shippers.
“Synergy Marine is on the cutting edge of technology in the maritime sector, and we’re honored to be part of their journey to work with owners in their transition away from fossil fuels,” said Mukesh Chatter, President and CEO at Alsym Energy. “By manufacturing batteries from low-cost, readily available materials that are inherently non-flammable and non-toxic, we’re providing an economically-viable way to help them decarbonize while also lowering operating expenditures and insurance costs associated with lithium and cobalt-based battery technologies.”
About Alsym™ Energy
Alsym Energy is a leading developer of advanced low-cost, high-performance rechargeable batteries made from readily available materials that are inherently non-flammable and non-toxic, providing an economically viable alternative to lithium-based technologies. The company is focused on commercial development and mass production of batteries for use in applications including passenger electric vehicles and two-wheelers, marine shipping, and stationary energy storage to enable a zero-carbon future. To learn more, please visit www.alsym.com .
About Synergy Marine Group
Headquartered in Singapore, Synergy’s hallmarks are its through-life approach to asset management and ability to develop custom-designed thought partnership strategies with leading owners. Spanning across a network of 25 offices in 13 countries and employing more than 18,000 seafarers, Synergy manages a fleet of over 500 vessels including the most complex LNG (including FSUs), LPG and vast 20,000+ TEU container ships, as well as oil and chemical tankers, car carriers and bulk carriers. With a strong focus on crew wellbeing, digitalization and environmentally responsible policies, Synergy is at the forefront of transforming the ship management industry. For more information visit www.synergymarinegroup.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220720005100/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Phase 1 Results for its TGFβR2×PD-1 Bispecific Antibody in Advanced Colorectal Cancer and KRAS G12D Inhibitor in Advanced Pancreatic Ductal Adenocarcinoma19.10.2025 19:30:00 CEST | Press release
Data presented at ESMO 2025 show INCA33890, a TGFβR2×PD-1 bispecific antibody, has the potential to be an effective treatment in microsatellite stable (MSS) colorectal cancerPlanned initiation of registrational program for INCA33890 in MSS colorectal cancer in 2026Maturing data for INCB161734, a KRAS G12D inhibitor, shows a favorable safety profile and evidence of clinical benefit in heavily pre-treated pancreatic ductal adenocarcinoma (PDAC) patientsIncyte will expand on the results from the oral presentations at an in-person and webcasted event on Sunday, October 19, 2025, from 1:30 – 3:00 p.m. EDT (7:30 – 9:00 p.m. CEST) Incyte (Nasdaq:INCY) announced the first clinical data evaluating its TGFβR2×PD-1 bispecific antibody (INCA33890) for patients with microsatellite stable (MSS) colorectal cancer; and its potent, selective and orally bioavailable KRAS G12D inhibitor (INCB161734) for patients with KRAS G12D mutations, specifically pancreatic ductal adenocarcinoma (PDAC). The data were
Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment19.10.2025 11:15:00 CEST | Press release
New data from pivotal Phase 3 ROSELLA trial reinforce relacorilant plus nab-paclitaxel improves progression-free and overall survival in patients with platinum-resistant ovarian cancer, with no need for biomarker selection – including in people who progressed while on or after taking a PARP inhibitor, a patient population with particularly poor prognosis Corcept expands BELLA trial to three study arms: (i) platinum-resistant ovarian cancer, (ii) platinum-sensitive ovarian cancer and (iii) endometrial cancer Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today shared new late-breaking data from its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer at the European Society for Medical Oncology (ESMO) 2025 Annual
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release
– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura
ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release
ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release
With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom